Literature DB >> 9503176

Fibrinogen as a risk factor for coronary heart disease and mortality in middle-aged men and women. The Scottish Heart Health Study.

M Woodward1, G D Lowe, A Rumley, H Tunstall-Pedoe.   

Abstract

AIMS: Fibrinogen was measured in 5095 men and 4860 men aged 40-59 in a random population sample from 25 districts of Scotland recruited during 1984-87: the Scottish Heart Health Study. Fibrinogen was then related to the chance of fatal and non-fatal coronary events and death from any cause during a subsequent follow-up period of around 8 years. METHODS AND
RESULTS: Fibrinogen was measured by the Clauss assay. The effect of fibrinogen on coronary heart disease and death was assessed through age-adjusted means and Cox proportional hazards regression models, accounting for age, cotinine (a measure of tobacco smoke inhalation) and 11 other major coronary risk factors. Fibrinogen was found to be an important risk factor for coronary heart disease in men and women, with and without pre-existing coronary heart disease. There appears to be a threshold effect, with those in the highest fifth of the distribution having a much increased risk. Estimated age-adjusted hazard ratios by sex and pre-existing coronary heart disease group for the highest to lowest fifth of fibrinogen range between 1.93 and 4.86. Fibrinogen is also important as a risk factor for coronary death and all-causes mortality, with a similar threshold effect. Comparing the two extreme fifths, the hazard ratios for coronary death are 3.01 and 3.42, and for all-cause mortality are 2.59 and 2.20, for men and women respectively. Adjustment for cotinine reduces the hazard ratios, but further adjustment for the other 11 risk factors has little effect for coronary heart disease events. After full adjustment there is a remaining significant (P < 0.05) hazard ratio for coronary death and death from any cause and for a coronary heart disease event for those free of coronary heart disease at baseline, amongst men, comparing the highest to the lowest fifth.
CONCLUSION: Fibrinogen is a strong predictor of coronary heart disease, fatal or non-fatal, new or recurrent, and of death from an unspecified cause, for both men and women. Its effect is only partially attributable to other coronary risk factors, the most important of which is smoking.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9503176     DOI: 10.1053/euhj.1997.0573

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  16 in total

1.  Sleep-disordered breathing and prothrombotic biomarkers: cross-sectional results of the Cleveland Family Study.

Authors:  Reena Mehra; Fang Xu; Denise C Babineau; Russell P Tracy; Nancy S Jenny; Sanjay R Patel; Susan Redline
Journal:  Am J Respir Crit Care Med       Date:  2010-05-27       Impact factor: 21.405

Review 2.  Biomarkers and HIV-associated cardiovascular disease.

Authors:  Jason V Baker; Daniel Duprez
Journal:  Curr Opin HIV AIDS       Date:  2010-11       Impact factor: 4.283

3.  Analysis of traditional and emerging risk factors in premenopausal women with coronary artery disease: A pilot-scale study from North India.

Authors:  Rajesh Vijayvergiya; Divya Kapoor; Ajay Aggarwal; Sonal Sangwan; Vanita Suri; Veena Dhawan
Journal:  Mol Cell Biochem       Date:  2017-03-23       Impact factor: 3.396

Review 4.  Fibrinogen and coronary risk.

Authors:  W Koenig
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

5.  High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection.

Authors:  Jason Baker; Woubeshet Ayenew; Harrison Quick; Katherine Huppler Hullsiek; Russell Tracy; Keith Henry; Daniel Duprez; James D Neaton
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

6.  Proteome Profiling of Vitreoretinal Diseases by Cluster Analysis.

Authors:  Tomomi Shitama; Hideyuki Hayashi; Sumiyo Noge; Eiichi Uchio; Kenji Oshima; Hisao Haniu; Nobuaki Takemori; Naoka Komori; Hiroyuki Matsumoto
Journal:  Proteomics Clin Appl       Date:  2008-09       Impact factor: 3.494

7.  DNA methylation age is associated with an altered hemostatic profile in a multiethnic meta-analysis.

Authors:  Cavin K Ward-Caviness; Jennifer E Huffman; Karl Everett; Marine Germain; Jenny van Dongen; W David Hill; Min A Jhun; Jennifer A Brody; Mohsen Ghanbari; Lei Du; Nicholas S Roetker; Paul S de Vries; Melanie Waldenberger; Christian Gieger; Petra Wolf; Holger Prokisch; Wolfgang Koenig; Christopher J O'Donnell; Daniel Levy; Chunyu Liu; Vinh Truong; Philip S Wells; David-Alexandre Trégouët; Weihong Tang; Alanna C Morrison; Eric Boerwinkle; Kerri L Wiggins; Barbara McKnight; Xiuqing Guo; Bruce M Psaty; Nona Sotoodenia; Dorret I Boomsma; Gonneke Willemsen; Lannie Ligthart; Ian J Deary; Wei Zhao; Erin B Ware; Sharon L R Kardia; Joyce B J Van Meurs; Andre G Uitterlinden; Oscar H Franco; Per Eriksson; Anders Franco-Cereceda; James S Pankow; Andrew D Johnson; France Gagnon; Pierre-Emmanuel Morange; Eco J C de Geus; John M Starr; Jennifer A Smith; Abbas Dehghan; Hanna M Björck; Nicholas L Smith; Annette Peters
Journal:  Blood       Date:  2018-07-24       Impact factor: 22.113

8.  Multiple inflammatory biomarkers in relation to cardiovascular events and mortality in the community.

Authors:  Renate B Schnabel; Xiaoyan Yin; Martin G Larson; Jennifer F Yamamoto; João D Fontes; Sekar Kathiresan; Jian Rong; Daniel Levy; John F Keaney; Thomas J Wang; Joanne M Murabito; Ramachandran S Vasan; Emelia J Benjamin
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-05-02       Impact factor: 8.311

Review 9.  Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.

Authors:  Gillian M Keating; Douglas Ormrod
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 10.  Exercise-induced changes in coagulation and fibrinolysis in healthy populations and patients with cardiovascular disease.

Authors:  Christopher J Womack; Paul R Nagelkirk; Adam M Coughlin
Journal:  Sports Med       Date:  2003       Impact factor: 11.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.